Varian Medical Systems agrees to pay about $35 million to settle a patent infringement lawsuit brought by the University of Pittsburgh, after a federal appeals court overturns a portion of its $100 million loss to Pitt.
Varian Medical (NYSE:VAR) said it settled its patent infringement beef with the University of Pittsburgh for $35 million, after a federal appeals court overturned a portion of the $100 million award Pitt won in 2012.
RefleXion Medical secures an $11.6 million Series A funding round in support of its cancer-targeting bio-guided radiation therapy system.
California-based medtech group RefleXion Medical touted an $11.6 million Series A fundraising round, hoping to use the new funds to expand research & development efforts for its guided radiation therapy technology.
Halt Medical has big plans for its Acessa System for treating uterine fibroids, having raised nearly $93 million in efforts to restructure debt and fund its commercial efforts.
California women's health company Halt Medical is raising capital ahead of a major commercial bid for its Acessa radiofrequency-based uterine fibroid treatment.
Advanced Medical Isotope Corp. considers pursuing regulatory down-classification for its brachytherapy cancer product.
Washington-based Advanced Medical Isotope Corp. is evaluating its options for U.S. market approval of its proprietary brachytherapy cancer product, the company announced.
Radiosurgery systems maker Accuray lands summary judgment in trade secrets lawsuit filed by former supplier Rotary Systems.
California medtech maker Accuray (NSDQ:ARAY) tallied a win in a trade secrets lawsuit filed by a former supplier, announcing that a Minnesota court awarded summary judgment against Rotary Systems.
Radiosurgery systems maker Varian affirms its 2014 outlook with 5% year-over-year growth in Q1, even as per-share earnings fall short of expectations.
Palo Alto, Calif.-based Varian Medical (NYSE:VAR) started its fiscal year with moderate growth and a reaffirmed outlook on 2014, but per-share earnings fall short of analysts' projections.
Accuray slashes Q2 losses and ups its earnings expectations for the year, prompting a 13% boost from Wall Street.
California radiation oncology systems maker Accuray (NSDQ:ARAY) scored major Wall Street points with its 2nd quarter financial report, with shares soaring on news of lowered losses and increased guidance for the year.